Abstract Organoids are three-dimensional structures derived from either pluripotent stem cells or adult stem cells, consisting of multiple cell types that interact with one another. They are highly sought after for research in organ development, disease modeling, and drug testing. Organoids can be engineered to replicate specific disease conditions, enabling researchers to study disease progression and design therapeutic modalities. We have used recombinant monoclonal antibodies, produced using a proprietary B-cell immortalization technique and a high-yield expression system, for characterizing organoids. These antibodies provide consistent performance across various experimental conditions and exhibit high specificity and sensitivity, allowing for precise detection of target proteins in biological samples. They can be utilized to identify specific cell types during organoid development, study the time-dependent expression of proteins, and analyze the interactions among multiple cell types during development. We have examined organoid development and maturation through immunohistochemistry using selected recombinant antibodies. Immunohistochemistry analysis conducted on normal liver tissue sections, as well as progenitor and mature organoid sections, revealed remarkable staining patterns for targets such as FOXA2, HNF4alpha, and Keratin 7. These applications may significantly enhance our understanding of the mechanisms involved in tissue development and disease progression. Citation Format: Mark Machak, Nicole Schultz, Rudra Bhowmick, Joseph Boyd, Fong-Cheng Pan, John Larsen, Vi Chu, Mary Mills, Chandra Mohan, I-Fang Ling, Arazo Saadat, Mark A. Santos. Characterizing organoid maturation and disease progression through recombinant monoclonal antibodies abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 743.
Machak et al. (Fri,) studied this question.